New real-world evidence underscores the substantial public health value of Sanofi’s BEYFORTUS® (nirsevimab) in preventing infant hospitalizations due to Respiratory Syncytial Virus (RSV). A comparison study reported during the 43rd Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID) revealed a BEYFORTUS immunization program in Spain reduced infant RSV hospitalizations by 69.0% in the 2024-2025 season compared to a 26.7% reduction in the UK, which had only an RSVpreF maternal vaccine program.
Also supporting these results, fresh durability information from the HARMONIE Phase 3b clinical trial, released in The Lancet Child & Adolescent Health, showed that BEYFORTUS had continued high efficacy, lowering RSV hospitalizations in infants by 82.7% over six months. This long-term protection lasts longer than the usual five-month RSV season.
BEYFORTUS® is a long-acting monoclonal antibody intended to provide passive immunity against RSV in infants. The results of the study justify the use of infant immunization programs with BEYFORTUS® as a strategy to decrease the burden of RSV among pediatric populations.
About BEYFORTUS®
BEYFORTUS is the initial immunization indicated for all infants to guard against RSV illness during their first RSV season, including infants born prior to or during the RSV season, at term or preterm and otherwise healthy, or who have certain underlying health conditions. BEYFORTUS is also intended to guard children 24 months of age and younger who are still at risk for serious RSV illness during their second RSV season.
As a long-acting antibody administered directly to newborns and infants as a single dose, BEYFORTUS provides immediate and direct protection against RSV lower respiratory tract disease without the need for immunologic activation. An additional dose of BEYFORTUS is indicated for children who have undergone cardiac surgery with cardiopulmonary bypass as soon as the child is stable from surgery. A second dose of BEYFORTUS is also recommended for children aged 24 months and younger, based on body weight, who are still at risk for serious RSV disease through their second RSV season. Administration of BEYFORTUS can be scheduled during the season of RSV.
Last Modified:
